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 Introduction. Histoplasmosis, a fungal disorder characterized by a wide spectrum of manifestations 
that range from subclinical infections to disseminated processes, affects both immunocompetent 
and immunosuppressed individuals. Histoplasmosis is not a reportable disease in Colombia and 
consequently, a survey was designed to collect histoplasmosis cases diagnosed in the country. 
Objective. The aim of this work was to analyze the data collected from 1992 to 2008.
Materials and methods. The survey included demographic data, risk factors, clinical manifestations, 
imaging data, diagnostic methods and antifungal treatment. Patients were grouped according to risk 
factors and comparisons of the various findings were done.
Results. A total of 434 surveys were gathered from 20 of the country’s Departments. Most patients 
(96.1%) were adults, 77% were males with a mean age of 38.4 years. Only 3.9% were children less than 
15 years of age. In the adult population, AIDS was reported in 70.5% of the cases; additionally, in 7.0% 
patients other immunosuppressive conditions were informed. The most frequent clinical manifestations 
were fever (76.1%), cough (54.8%) and constitutional symptoms (56.8%). X rays abnormalities were 
represented mainly by infiltrates (65.9%) and nodules (17.1%). Diagnosis was made by microscopic 
observation of H. capsulatum in 49.6% patients, by culture in 58.0% and by serological test in 14.6% 
cases. Antifungal use was recorded in 52.5% cases. 
Conclusions. Histoplasmosis is frequent in Colombia, especially in certain risk factor groups such 
as the HIV-infected population. Data collected from this large number of cases has allowed valid 
comparisons on various aspects of histoplasmosis in Colombia.
Key words: histoplasmosis, surveillance, acquired immunodeficiency syndrome, children, disseminated 
histoplasmosis, Colombia.
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Histoplasmosis en Colombia: resultados de la encuesta nacional, 1992-2008 
Introducción. La histoplasmosis está caracterizada por variadas manifestaciones que van desde 
la afección subclínica a la enfermedad diseminada, y suele presentarse tanto en huéspedes 
inmunocompetentes como inmunosuprimidos. Como la enfermedad no es de notificación obligatoria en 
Colombia, se diseñó una encuesta para recolectar información de los casos diagnosticados en el país.
Objetivo. El objetivo de este trabajo fue analizar los datos recolectados desde 1992 hasta 2008.
Materiales y métodos. La encuesta incluyó datos demográficos, factores de riesgo, manifestaciones 
clínicas, estudios de imágenes, métodos diagnósticos y tratamiento antifúngico. Los pacientes se 
agruparon de acuerdo con los factores de riesgo y se compararon los correspondientes hallazgos.
Resultados. Se examinaron 434 encuestas provenientes de 20 de los departamentos colombianos. 
La mayoría (96,1 %) correspondían a adultos, 77 % eran hombres con edad promedio de 38,4 años, 
y sólo 3,9 % eran niños o adolescentes. En los adultos, 70,5 % tenían sida y 7 % presentaban otra 
inmunosupresión. Las manifestaciones predominantes fueron fiebre (76,1 %), tos (54,8 %) y síntomas 
constitucionales (56,8 %). En las radiografías, las anormalidades fueron principalmente infiltrados (65,9 
%) y nódulos (17,1 %). El diagnóstico se estableció por observación microscópica de H. capsulatum 
en 49,6 % casos, por cultivo en 58 % y por pruebas serológicas en 14,6 %. El tratamiento se informó 
sólo en 52,5 % casos.
Conclusiones. Se demostró que la histoplasmosis es frecuente en Colombia, especialmente en grupos 
de riesgo como son los pacientes infectados con el VIH. El análisis de este número relevante de pacientes 
permitió establecer comparaciones válidas sobre aspectos de la histoplasmosis en nuestro país.
Palabras clave: histoplasmosis, vigilancia, síndrome de inmunodeficiencia adquirida, niños, 
histoplasmosis diseminada, Colombia.
Histoplasmosis is an endemic fungal infection of 
the Americas caused by the thermally dimorphic 
soil inhabitant fungus Histoplasma capsulatum var. 
capsulatum (1). Endemic areas have been defined 
in the United States especially in the Ohio and 
Mississippi river valleys, as well as in Central and 
South America (1-3).
H. capsulatum and its recently described clades, 
grow in vitro at 25 °C and in the environment as a 
mold, which reproduces asexually by microconidia 
(2-5 μm), considered as the infectious propagules, 
and also by macroconidia (8-14 μm). At 37 °C in 
vitro and in the infected tissues, it grows as a yeast 
cell reproducing by blastoconidia, considered the 
parasitic phase of the fungus (4).
In normal hosts most infections (over 90%) 
are asymptomatic or self-limited; however, in 
a few of these hosts, histoplasmosis may be a 
severe pulmonary disease requiring antifungal 
therapy. On the contrary, in immunocompromised 
individuals, such infections are not only severe but 
result in progressive disease with hematogenous 
dissemination and a variety of clinical manifestations. 
Any organ can be affected, especially lungs, bone 
marrow, skin, brain, adrenal glands, and the 
gastrointestinal tract (4,5).
In the 1980s, disseminated histoplasmosis due 
to H. capsulatum was described in HIV-infected 
patients in the histoplasmosis endemic areas of 
the United States. Disseminated histoplasmosis 
was later included in the list of opportunistic 
infection defining AIDS. Despite the increased use 
of highly active antiretroviral therapy (HAART), 
histoplasmosis remains an important opportunistic 
infection among HIV patients in endemic areas and 
frequently appears as the first manifestation of HIV 
infection or as the AIDS-defining illness (6-9).
Due to the fact that histoplasmosis is not a 
reportable disease in Colombia and recognizing 
the need to better understand the characteristics of 
this mycosis in the country, the medical mycology 
groups of the Instituto Nacional de Salud (INS) and 
the Corporación para Investigaciones Biológicas 
(CIB) prepared in 1997 a questionnaire following 
the indications of the European Committee of 
Medical Mycology (10) and with their authorization 
distributed it amply to clinicians and laboratory 
personnel. Additionally, the organizing laboratories 
transferred to the questionnaires data from 
patients (n=30) diagnosed during earlier periods 
(1992-1996). Such a document was also sent 
along with mycological tests reports to physicians 
and personnel in charge of diagnosing infectious 
diseases asking for their voluntary cooperation in 
completing the requested information.
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The aims of the survey were to obtain demographic 
data from Colombian patients with the mycosis, to 
determine risk factors, clinical presentation, imaging 
data, methods by which the infection was diagnosed 
and antifungal treatment prescribed. Data collected 
from 1992 to 2008 is presented here. A preliminary 
report was published in 2000 (11).
Materials and methods
Data to be recorded in the questionnaire included 
patient’s demographics, date of diagnosis, 
place of birth and residence, risk factors (HIV 
infection, corticosteroids, autoimmune disorders, 
transplantation, solid tumor, hematologic 
malignancy, others), occupational exposure to bird 
excreta or bat guano, demolition work, visit to caves 
and soil removal activities, among others. Data on 
the origin of the clinical sample, the mycological 
tests leading to diagnosis (direct examination, 
cultures, immunodiffusion (ID) bands H and M, 
complement fixation (CF) titers were also taken 
into consideration (12).
Clinical findings recorded included signs and 
symptoms: fever, weight loss, pleuritic pain, anorexia, 
adynamia, vomiting, diarrhea, expectoration, 
meningeal symptoms, erythema nodosum, hepato-
splenomegaly and adenomegalies, radiographic 
and hematologic abnormalities, as well as other 
lesions attributable to the mycoses. In HIV patients, 
data included CD4+ lymphocyte counts, HAART 
and indications on whether or not histoplasmosis 
had been a marker of AIDS. Finally, information on 
the type of antifungal treatment administered was 
added to the files (Supplement 1, on line version). 
Once completed, the questionnaires were sent 
to one of the coordinating institutions for their 
recording and analysis.
Definition of histoplasmosis was based in the 
presence of a compatible clinical record and in, 
at least, one of the following laboratory-based 
parameters (4):
Isolation of •	 H. capsulatum in culture.
A positive direct examination by Wright or other •	
histological (silver methenamine, PAS) stains.
A reactive ID test with bands M/H or both, done •	
in the reference laboratories only (INS and CIB) 
(12).
A reactive CF test with a 1:32 titer with either the •	
H antigen (histoplasmin, a fungus mycelia form 
filtrate) or with the Y antigen (whole yeast cells). 
Also done in the two reference laboratories (INS 
and CIB) (12).
Incidences were calculated by departments taking 
into account the mean number of cases in four 
years with the estimated 2005 population.
Data were stored in a database in Excel® (Microsoft, 
Redmond, WA) and processed with the statistical 
programs SPSS® 16.0 (SPSS Inc., Chicago, 
Illinois) and EPIDAT 3.1 (OPS – Xunta de Galicia). 
A descriptive analysis of all patients included in the 
study was made with the quantitative data being 
presented as averages and standard deviation, 
and the qualitative data as absolute frequency and 
percentage. For the bivariate analysis individuals 
were split in 4 groups according to the information 
available in the questionnaire, as follows: patients 
with AIDS, patients with other immunosuppression, 
with known occupational risk and with no 
information available. The corresponding results 
were compared among themselves by means of the 
chi2 with the Yates correction or the Fischer exact 
test according to the need. The Student t test was 
employed to compare the continuous variables. 
A value of p<0.05 was considered as statistically 
significant. Data are presented with a p value and 
odds ratios with confidence intervals of 95% (13).
Ethics statement
The present study received the approval of the 
Ethics Committee of the CIB. Its implementation 
was subjected to the principles stated in the Helsinki 
declaration concerning medical research in human 
beings. Due to the descriptive character of the 
study and considering that the research reported 
was exempt of any risk to the subjects whose data 
were employed; their informed consent was not 
obtained. This is in accordance with Resolution 
8430 issued in 1993 by the Ministry of Health of 
Colombia in charge of regulating medical research 
in the country. Furthermore all clinical and para-
clinical procedures employed were those required 
by the consulting physician for the establishment 
of the diagnosis with no extra tests being carried. 
The authors did not intervene with the patients and 
only processed their samples as ordered by the 
physician in charge.
Results
Questionnaires, yearly distribution and origin
A total of 434 questionnaires from histoplasmosis 
patients were gathered in 16 years (1992-2008) 
and their distribution were as follows: 1992-1996 
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(n=30); 1997-2000 (n=98); 2001-2004 (n=149); 
2005-2008 (n=157).
The patients originated in 20 of the 32 (62.5%) of 
the Colombian political divisions (Departments) and 
of the Capital District. In figure 1 a Colombian map 
is presented with the number and percentages of 
cases by Department with more than five cases. The 
other departments submitting cases were Cauca 3 
(0.69%); Cesar, Chocó, Tolima and Risaralda, 2 
each (0.46%). Arauca, Atlántico, Bolívar, Caquetá, 
Casanare, Córdoba, Huila and Sucre had one case 
each (0.23%).
Incidences are presented in supplement 2 (http://
www.revistabiomedica.org/index.php/biomedica/
article/view/348) on line version. The only change 
observed was in Antioquia where in the period 
2001-2004, the incidence was 0.317 per 100,000 
habitants to increase in 2005-2008: to 0.462 per 
100,000 habitants.
Demographic data
From the 434 questionnaires available, 417 (96.1%) 
corresponded to adult patients and the remaining 
17 (3.9%) to children less than 15 years of age. 
supplement 3, on line version, shows patient 
distribution according to the various parameters 
taken into consideration for the study.
The characteristics of histoplasmosis in the latter 
population are shown in table 1. Findings of 
importance were the predominance of boys 11 
(64.7%) and the presence of immunosuppression 
in 6 patients, 2 (11.8%) with AIDS and 4 (29.4%) 
with diverse hematologic malignancies. In 7 of the 
10 (70%) patients with chest X-rays, abnormalities 
were recorded. In this series, the clinical presentation 
of histoplasmosis in 17 children indicated that 14 of 
them had the progressive disseminated form; only 
one case could take as representing the acute form 
of the mycosis. Data were considered insufficient 
in the remaining cases. The diagnostic methods 
rendering higher positive results were the isolation 
of H. capsulatum in culture and the presence of a 
reactive ID test, 85.7% each. 
As shown in supplement 4, on line version, the 
417 adult patients had a mean age of 38.4 (+12.3) 
years. The majority, 321 (77%) were males and 
the remaining 96 (23%) females. The global 
ratio male: female was 3:1; when occupational 
factors existed, the ratio was 1.5:1; if a non-AIDS 
immunosupression had been reported, this ratio 
Figure 1. Histoplasmosis, number and percentage of cases by Department
Cundinamarca
Antioquia
Caldas
Bolívar
Boyacá
Córdoba
Cauca
Risaralda
Guaviare
Tolima
Huila
Meta
Atlántico
Cesar
Quindío
Valle del Cauca
Norte de Santander
Archipiélago
de San Andrés
y Providencia
Guainía
Putumayo
Caquetá
Magdalena
Sucre
Casanare
Arauca
Vichada
Bogotá
Nariño
La Guajira
Santander
Amazonas
Vaupés
Chocó
Department   n               %
Antioquia                            257      59.2
Valle                                     68      15.6
Cundinamarca (Bogotá)       53     12.2
Norte de Santander              13       3.0
Caldas                                   11      2.5
Meta                                        7       1.6
Santander                               6        1.4
Others (n=13)                        19       4.4
Total                                     434             
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Table 1. Histoplasmosis in children less than 15 years (n=17) (1992-2008)
Demographic characteristics
Age at diagnosis (x- SD+)
Average age (years) 6.52 (+3.93)
Range 1-14
Sex     n (%)
Male    11 (64.7)
Risk factors            n (%)
AIDS 2 (11.8)
Hematologic cancer  4 (23.5)
Environmental exposure 3 (17.6)
Unknown  8 (47.1)
Symptoms              n (%)
Fever 15 (88.2)
Constitutional symptoms  7 (41.1)
Cough  7 (41.1)
Headache  5 (29.4)
Vomiting 4 (23.5)
Lymphadenopathy 6 (35.3)
Weight loss  3 (17.6)
Meningeal syndrome  2 (11.7)
Hepato/splenomegaly  6 (35.3)
Anemia  6 (35.3)
Trombocytopenia  1 (5.9)
Dyspnea  2 (11.8)
Diarrhea  2 (11.8)
Skin lesions  2 (11.8)
Bone lesions  1 (5.9)
Chest X rays (n=10)                n (%)
Normal  2 (20.0)
Abnormal  7 (70.0)
Infiltrates only 3 (30.0)
Calcifications and infiltrates 2 (20.0)
Nodules only 1 (10.0)
Cavitations and infiltrates 1 (10.0)
Symptoms evolution (months) (SD+): 2.34 (+1.99) 
Diagnostic method            n (%)
Culture 3 (17.6)
Microscopic observation 2 (11.8)
Culture + microscopic observation 3 (17.6)
Serological test 9 (53.0)
Results of the diagnostic tests     +/ total (%)
Histopathology  5/9 (55.6) 
Culture  6/7 (85.7) 
Immunodiffusion 12/14 (85.7) 
Band H 2 (16.7) 
Band M 9 (75.0) 
Bands H and M  1 (8.3) 
Complement fixation  9/14 (64.3) 
(≥	1:32)	 6/14	(42.9)	
(= 1:16) 3/14 (21.4) 
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was 1.2:1. Nonetheless, in AIDS patients such ratio 
was 5.5:1. When analyzing time and sex ratios in 
the latter group, it was found that in the period 
1995-1999, it increased to 9.3:1 and between 2004-
2008, it was 5.8:1 but with no significant difference 
(p=0.3).
Risk factors
AIDS was reported in 294/417 (70.5%) of 
the cases while in 29 (7.0%) there was other 
immunosuppressive conditions such as use of 
steroids in 13 (44.8%), presence of neoplasia in 
7 (24.1%), transplantation in 4 (13.8%), diabetes 
in 2 (6.9%), cirrhosis in 1 (3.4%), alcoholism or 
malnourishment in 1 (3.4%) case each. In 51 
(12.2%) patients an environmental factor leading to 
H. capsulatum exposition such as contact with bat 
guano, bird excreta, cave or wheel entry, demolition 
work or soil removal, was indicated in the records. 
On this token, 23 patients had been involved in six 
different histoplasmosis outbreaks. In 43 (10.3%) 
patients the records did not reveal the presence or 
absence of a risk factor.
At time of diagnosis, 43 of the 294 AIDS patients 
(14.6%) had a mean of 66.5 (±82.1) T CD4+ 
lymphocytes/μl. In 81 (27.6%) antiretroviral treatment 
had been given. Histoplasmosis was the AIDS 
defining condition in 86 (29.3%) of these patients.
Demographic data, age distribution and sex-
related factors in AIDS and non-AIDS patients 
with histoplasmosis are presented in figures 2a 
and 2b.
Clinical aspects
The pertaining data was recorded in 394 out of 
the 417 (94.5%) questionnaires received (table 2). 
Mean duration of symptoms before diagnosis was 
3.42 (±6.5) months. In AIDS patients it was 2.68 
(±3.92), in other immunosuppression states, 6.10 
(±6.66), in those with occupational risk factors 5.53 
(±12.22) and when no information was given, it was 
4.43 (±7.18). There was a significant difference 
between the mean duration of symptoms, in months, 
before diagnosis between AIDS (2.68±3.92) and 
non-AIDS patients (5.3±9.27), p=0.01.
In the 394 patients referred to above, the most 
frequent clinical manifestation was fever recorded in 
300 (76.1%) of them. Other frequent findings were 
cough present in 216 (54.8%) and constitutional 
symptoms (asthenia, adynamia, anorexia) seen 
in 224 (56.8%) patients. The latter were informed 
more regularly (178/280, 63.6%) in the AIDS group 
than in the remaining patients (table 2).
Diarrhea, odynophagia/dysphagia and seizures 
were recorded almost exclusively in AIDS patients. 
Hematologic abnormalities, especially anemia, were 
observed in the same group of patients (47.9%), 
as well as in those with other immunosuppresion 
(27.6% p<0.01). Skin lesions were recorded in 109 
(38.9%) of the AIDS patients, in 5 (17.2%) in those 
with other immunosuppressive conditions (p=0.03) 
and in 2 (4.8%) of the patients with occupational risk 
factors (p<0.01). In 21 (5.3%) patients meningeal 
symptoms were recorded although H. capsulatum 
infection of the CNS by was demonstrated only in 
9 (2.3%) of them.
All patients coinfected with HIV could be considered 
as progressive disseminated histoplasmosis, as 
well as the cases with other immunossupressive 
conditions. In the 51 cases classified as 
occupational, the data revealed disseminated 
histoplasmosis in 6 but the 23 patients belonging 
to outbreaks had the acute form clinically restricted 
Figure 2b. Demographic data in Colombian non AIDS patients 
with histoplasmosis (n=138) ** p< 0.01
Figure 2a. Demographic data in Colombian AIDS patients with 
histoplasmosis (n=296)
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to lungs. In those patients classified in the non-risk 
factor group that also included those that had had no 
occupational exposure (n=44), 24 (54.5%) showed 
only pulmonary involvement probably representing 
the acute form of histoplasmosis, 18 (40.9%) 
had more than one abnormal, fungal-colonized 
sites indicative of progressive disseminated 
histoplasmosis while in the remaining 2 cases 
(4.5%) the data provided was not enough to allow 
establishment of the clinical form.
Lung X-rays
Table 3 illustrates the radiographic data according 
to the risk factor. In 67 out of the 394 (22.8%) 
patients, the X-rays were within normal limits 
while in 294 (74.6%) abnormalities were revealed 
and represented mostly by infiltrative lesions194 
(66.2 %).
Diagnostic methods
In the 417 patients included in the study, the 
tests employed to establish the diagnosis of 
histoplasmosis were not always the same and at 
times, more than one method was applied. The 
diagnosis of histoplasmosis was made by isolation 
in culture of H. capsulatum, microscopic observation 
of yeast cells using Wright or histological stains, 
a combination of the two or by serological tests. 
In the 417 adult patients, diagnosis by culturing 
H. capsulatum was done in 58%, by microscopic 
observation in 49.6% and by serological test in 
14.6%. For each of the four groups analyzed, namely, 
Table 2. Clinical manifestations in 394* adult patients with histoplasmosis (1992-2008)
 Risk factor n (%)
Clinical AIDS OI1 Occupational NR2 Total 
manifestation (n=280) (n=29) (n=42)   (n=43)  (n=394) *
Fever3 229  (81.8) 19  (65.5) 31  (73.8) 21  (48.8) 300  (76.1)
Constitutional symptoms4 178  (63.6) 12  (41.4) 19  (45.2) 15  (41.2) 224  (56.8)
Cough  160  (57.1) 13  (44.8) 27  (64.3) 16 (34.9) 216  (54.8)
Anemia5  134  (47.9) 8  (27.6) 2  (4.8) 2  (4.7) 146  (37.1)
Adenopathies6 122  (43.6) 2  (6.9) 7  (16.7) 10  (23.3) 141  (35.8)
Skin lesions7  109  (38.9) 5  (17.2) 2  (4.8) 4  (9.3) 120  (30.5)
Hepatomegaly8  69  (24.6) 1  (3.4) 4  (9.5) 1  (2.3) 75  (19.0)
Mucosal lesions  58  (20.7) 5  (17.2) 4  (9.5) 7  (16.3) 74  (18.8)
Headache  41  (14.6) 3  (10.3) 8  (19.0) 6  (14.0) 58  (14.7)
Splenomegaly 47  (16.8) 2  (6.9) 3  (7.1) 2  (4.7) 55  (14.0)
Weight loss  41  (14.6) 5  (17.2) 0 (0) 2  (4.7) 48  (12.2)
Chest pain  24  (8.6) 4  (13.8) 5  (11.9) 8  (18.6) 41  10.4)
Vomiting  32  (11.4) 3  (11.3) 2  (4.8) 2  (4.7) 39  (9.9)
Dyspnea  20  (7.1) 3  (10.3) 3  (7.1) 3  (7.0) 29  (7.4)
Diarrhea  27  (9.6) 0  (0) 0 (0) 0  (0) 27  (6.9)
Leukopenia  26  (9.3) 1  (3.4) 0 (0) 0  (0) 27  (6.9)
Thrombocytopenia  25  (8.9) 1  (3.4) 0 (0) 0  (0) 26  (6.6)
Sputum production 18  (6.4) 1  (3.4) 2  (4.8) 0  (0) 21  (5.3)
Meningeal signs  13  (4.6) 3  (10.3) 3  (7.1) 3  (7.0) 22  (5.6)
Erythema nodosum  3  (1.1) 1  (3.4) 4  (9.5) 0  (0) 8  (2.0)
Odynophagia/ Dysphonia 3  (1.1) 0  (0) 0 (0) 1  (2.3) 4  (1.0)
Seizures  4  (1.4) 0  (0) 0 (0) 0  (0) 4  (1.0)
Osteomuscular involvement  1 (0.4) 1  (3.5) 2  (4.8) 0  (0) 4  (1.0)
* Clinical data was not available in 23 patients
1 Other immunodeficiency: steroids (n=13), cancer (n=7), transplant (n=4), diabetes (n=2), cirrhosis (n=1), alcoholism (n=1), 
malnutrition (n=1)
2 No risk factor informed
3  OR=2.36, CI95% 1.04–5.39, p=0.04, between AIDS and other immunodeficiency 
4  OR=2.11, CI95% 1.11–4.03, p=0.04, between AIDS and occupational
5  OR=18.36, CI95% 4.35–77.43, p<0.01 between AIDS and occupational
6  OR=10.42, CI95%) (2.69–40.26), p<0.01, between AIDS and other immunodeficiency
  OR=3.86, CI95% (1.69–8.80), p<0.01, between AIDS and occupational
7  OR=3.06, CI95% (1.17–7.98) p=0.03, between AIDS and other immunodeficiency 
  OR=12.75, CI95% 3.02–53.82, p<0.01, between AIDS and occupational
8  OR=9.16, CI95% 1.22–68.55, p<0.01, between AIDS and other immunodeficiency 
 OR=3.10, CI95% 1.11–8.63, p=0.02, between AIDS and occupational
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AIDS, other immunosuppression, occupational and 
no factor declared, results of the diagnostic tests 
are presented in table 4.
As for the immunologic methods used, the ID test 
was done in 194 of the 417 cases on record proving 
reactive in 144 (74.2%) of them while the CF carried 
out in 189 cases, proved reactive en 92 (48.7%), 
(table 5). The ID revealed precipitin bands between 
70% and 85.7% of the cases while the CF was less 
reactive in the various groups tested, going from 
38.8% in AIDS patients to 57.1% in non-AIDS and 
showing 65% reactivity in those individuals having 
an occupational risk factor.
Treatment
From the 417 cases collected, information 
concerning antifungals used was recorded in 299 
(52.5%). Therapy based on a single medication 
was given to 219 (73.2%) patients while 80 
(26.7%) received combined therapy. Deoxycholate 
amphotericin B was used as single therapy in 
106 patients and in 72 of them was followed by 
different maintenance medications. Itraconazole 
was prescribed as single therapy in 83 patients 
or following amphotericin B in 62 patients; it was 
used with other antifungals in 5 cases. Fluconazole 
was given in 41 cases as single therapy or in 
combination. Ketoconazole was prescribed in 8 
instances (2.6%) while posaconazole was given as 
salvage therapy to 2 patients (0.7%).
Discussion
Among the endemic mycoses of the Americas the 
larger number of human cases reported correspond 
to histoplasmosis (1,3,4,14,15). Despite the fact that 
the larger endemic areas are those surrounding the 
Ohio and Mississippi River Valleys of the United 
Table 3. Chest X-rays abnormalities in 293/394* adult patients with histoplasmosis (1992-2008)
 Risk factor n (%)  
Abnormalities AIDS OI1 Occupational NR2 Total
 (n=211)  (n=20) (n=30)  (n=32)  (n=293)
Normal X rays 51  (23.5) 8  (31.6) 7  (23.3) 2  (6.3) 68  (23.2)
Infiltrates3 155  (73.5) 8  (40.0) 16  (53.3) 14  (43.7) 193  (65.9)
Nodules4 11  (5.2) 8  (40.0) 14  (46.7) 17  (53.1) 50  (17.1)
Cavitations  3  (1.4) 0  (0) 2  (6.7) 1  (3.1) 6  (2.0)
Fibrosis  0  (0) 1  (5.0) 0  (0) 0  (0) 1  (0.3)
Mass  0  (0) 0  (0) 0  (0) 2  (6.3) 2  (0.7)
Calcifications 8  (3.8) 1  (5.0) 1  (3.3) 2  (6.3) 12  (4.1)
* X-rays data was not furnished for 101/394 patients
1 Other immunodeficiency: steroids (n=6), cancer (n=7), transplant (n=3), diabetes (n=2), cirrhosis (n=1), alcoholism (n=1)
2 No risk factor informed
3 OR=4.15, CI95% 1.61–10.69, p<0.01, between AIDS and other immunodeficiency
 OR=3.16, CI95% 1.45–6.90, p<0.01, between AIDS and occupational
 OR=3.56, CI95% 1.66–7.63, p<0.01, between AIDS and unknown
4 OR=0.08, CI95% 0.03–0.24, p<0.01, between AIDS and other immunodeficiency
 OR=0.06, CI95% 0.02–0.16, p<0.01, between AIDS and occupational 
Table 4. Diagnostic procedures in 417 adult patients with histoplasmosis
Diagnosis  AIDS OI1 Occupational NR2 Total
 n=294 n=29 n=51 n=43 n=417
 n % n % n % n % n %
Culture 123 41.8 7 24.1 9 17.6 10 23.2 149 35.7
Microscopic observation 76 25.8 9 31.0 6 11.8 24 56.0 114 27.3
Culture and microscopic 71 24.2 7 24.1 7 13.7 8 18.6 93 22.3
observation 
Serologic test  24 8.2 6 21.0 29 57.0 1 2.3 61 14.6
1 Other immunodeficiency: steroids (n=13), cancer (n=7), transplant (n=4), diabetes (n=2), cirrhosis (n=1), alcoholism (n=1), 
malnutrition (n=1)
2 No risk factor informed
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States, this mycosis also occurs frequently in most 
Central and South American countries, Mexico 
(16,17), Panama (18), Venezuela (19,20) French 
Guyana (21), Brazil (22-26), and Argentina (27,28).
In Colombia, histoplasmosis is frequently informed 
in certain patient groups and, additionally, an 
important number of outbreaks have been reported. 
Nonetheless, the fact that it is not a reportable disorder 
hinders precise determination of its real incidence and 
impact on public health issues (29-33).
By means of the questionnaire adapted from the 
original format successfully used by the European 
Confederation of Medical Mycology Working Group 
(34), the present study represents the largest series 
of histoplasmosis cases informed in Colombia and 
Latin America and consists of 434 questionnaires 
filled in by physicians in charge of diagnosing 
and treating patients with the mycosis across the 
country during a 16-year period (1992-2008). Case 
distribution according to time of report showed a 
five-fold increase from 30 at start of the study to 
157 patients at the end; however, this may not 
reflect a more frequent presentation of the mycosis 
in the study’s latter period but a greater interest in 
the survey by the medical community.
Histoplasmosis cases were reported in 20 of 
the 32 (62.5%) political divisions in Colombia, 
including the Capital District, a finding indicative 
of the survey’s ample coverage. A striking number 
of patients (59.2%) corresponded to residents in 
the Department of Antioquia. These data disagree 
with the percentage of histoplasmin skin test 
reactors (10%) reported for healthy residents of 
such Department in a national survey (35) and 
contrast with other regions informing a higher (up 
to 35%) histoplasmin reactivity such as in the Valle 
Department represented here by a low number 
of case reports (15.6%). All the above suggest 
that other factors different to environmental 
circumstances influence case detection, such as 
a higher suspicion index by physicians and the 
local availability of diagnostic resources, as well as 
increased interest in the mycosis by the medical 
community in the area.
Another important finding in the series was the 
predominance of male patients (77%) who had 
a mean age of 38.4 (±12.3) years, as previously 
reported (29-31). By grouping the cases in non-
AIDS/AIDS it was noticed that in the former no 
differences existed by age or sex of the patients 
assigned to the various sub-groups, indicating 
that these factors play a negligible role in non-
immunosuppressed patients. In the AIDS group, on 
the other hand, young males 20 to 39 years of age 
predominated with significant differences being 
noticed among them, females and patients in other 
age groups. This finding agrees with the pattern of 
AIDS distribution in the Colombian population (36). 
Such a tendency has been reported in other series 
as well (2,3,7,17-19,23).
The number of children and adolescents albeit low 
(4.1%) was indicative of the non-selective nature of 
histoplasmosis, a mycosis known to afflict all ages 
(1,2). In this series, the ratio male to female was 
3:1 when no risk factor was reported although the 
presence of AIDS increased such ratio from 5.5:1 
in the early period to 5.8:1 in the latter part of the 
study but with no significant differences (p=0.3).
Among the risk factors recorded for the histo-
plasmosis patients reported here, AIDS was the 
Table 5. Results of the serological tests in adult patients with histoplasmosis (1992-2008) 
 Risk factor
 AIDS OI1 Occupational NR2 Total 
   n+/n total (%)
ID     
Band H  5/120  (4.2) 2/14  (14.3) 0/40  (0.0) 1/20 (5.0) 8/194  (4.1)
Band M  79/120  (65.8) 10/14  (71.4) 34/40  (85.0) 13/20  (65.0) 136/194  (70.1)
Total 84/120  (70.0) 12/14  (85.7) 34/40  (85.0) 14/20 (70.0) 144/194  (74.2)
CF      
<1:32  15/116  (13.0) 4/13  (30.7) 10/40 (25.0) 5/20  (25.0) 34/189  (17.3)
≥1:32  30/116  (25.9) 4/13  (30.7) 16/40  (40.0) 8/20  (40.0) 58/189  (30.7)
Total 45/116  (38.8) 8/13  (61.5) 26/40  (65.0) 13/20  (65.0) 92/189  (48.7)
ID: Immunodiffusion 
CF: Complement fixation (histoplasmin)
1 Other immunodeficiency: steroids (n=7), cancer (n= 4), diabetes (n=2), cirrhosis (1)
2 No risk factor informed
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predominant condition as shown by its occurrence 
in 70.5% of them; additionally, the mycosis was the 
AIDS defining illness in 29.3% cases. As expected, 
the patients’ T CD4+ mean counts were low, 66.5 
(±82.1) cells/μl, as only 27.6% of them had been 
receiving HAART at time of diagnosis. Late diagnosis 
was also important as indicated by the proportion 
of patients (29.3%) in whom full-blown AIDS was 
defined by clinically apparent histoplasmosis The 
coincidence of HIV and histoplasmosis has been 
noticed in most of the series reported (6-9,16-
18,21,24,26-28,29,31,37-39), but the role played 
by the mycosis as the AIDS defining opportunistic 
infection varies according to the country of report 
(37).
Since 1987 when progressive disseminated 
histoplasmosis became a marker of AIDS, it was 
assumed that the mycosis represented reactivation 
of latent foci as most patients were residents of the 
well-defined endemic areas of the United States, 
namely, the Ohio and Mississippi river valleys. 
Nonetheless, throughout the years it became 
evident that the primary infection occurs regularly 
in such areas (1,2,4,7,9).
Based on the data presented above and taking into 
consideration that histoplasmosis is endemic in 
certain Colombian regions (29,31,33), we believe 
that some of the patients could be considered as 
having had endogenous reactivation of a latent foci 
while in others, especially in those infected with the 
AIDS virus, histoplasmosis could well represent 
newly acquired infections from exposure to the 
fungus natural habitat.
Other immunosuppressive conditions such as 
steroid use, organ transplants, malnourishment, 
alcohol abuse, diabetes and cancer, were also 
recorded in small proportion of our patients (7.0%), 
such as reported by others (1,2,40). In 12.2% of 
the cases direct exposure to H. capsulatum (work 
with bat guano, bird excreta, exploration of caves 
or wells, demolition work or soil removal), was 
indicated in the records. All these circumstances 
have been reported as leading cause of fungal 
infection (1,2,5,32,33,41).
The pertaining clinical data were recorded in 
94.5% of the questionnaires received and the 
corresponding analysis indicated a mean duration 
of symptoms before diagnosis of 3.42 (±6.0) 
months, this period being shorter in AIDS patients 
2.68 (±3.92). A significant difference, p=0.01, was 
found between AIDS and non- AIDS patients, a 
difference already noticed in other reports and 
considered to be connected to the seriousness of 
the disease course in HIV patients (2,4,5,31,37-
39). The advanced stage of the latter infection 
in this series explains the clinical behavior of the 
mycosis, as observed by the lesser age found in 
this group as compared with those in the other risk 
factor groups; it may also explain, partially at least, 
the observed sex differences although here a more 
intense environmental exposure is also attributed 
to males.
Besides presenting a more rapid course, the 
clinical course of the AIDS patients was also more 
aggressive and exhibited peculiar characteristics 
rarely informed in other patients groups, such 
as indicated by hematologic abnormalities and 
frequency and severity of skin lesions, as described 
earlier (2,4,5,31,37-39). It should be noticed that 
skin lesions are seldom observed in North American 
patients (8,9). Virulence and tropism of the isolates 
predominant in the sub-continents may explain 
these differences (8) although late diagnosis in 
Latin American countries may also explain the more 
extensive dissemination observed in these patients.
The lungs X-ray also revealed significant differences 
among the groups with the AIDS patients showing 
infiltrative lesions more frequently (71.6%) than 
patients in other groups (63.5%). This tends to 
indicate that in AIDS patients, lung lesions are 
of shorter duration than in those whose immune 
responses are not depressed. On the other hand, 
nodules were predominantly recorded (53.1%) 
in the non-immunosuppressed patients and only 
in 17.1% of the HIV population, a difference that 
reflects the higher immune capacity of the former 
resulting in delayed fungal multiplication as reflected 
in the formation of more solid lesions characteristic 
of a later stage of the mycosis. Also of importance 
was the number of patients (23.2%) in whom no 
lung radiographic abnormalities were detected, a 
finding that indicates that X-ray exams are not as 
reliable as expected. Probably other image studies, 
such as CAT and MRI would detect the primary 
lung lesions (1,2,4,5).
In this study children and adolescents with 
histoplasmosis were only 17 but three findings 
were peculiar, namely, a certain predominance of 
boys (64.7%), the simultaneous presence of AIDS 
(11.8%) and of diverse hematologic malignancies 
(29.4%). Here again, histoplasmosis appears as 
an opportunistic disorder that profits from the host 
immune incapacity to induce a pathologic state of 
considerable importance (1,2).
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As it concerns serologic tests, the CF was 
unreliable in the AIDS population with only 48.7% 
of the patients proving reactive. On the other 
hand, the ID test revealed precipitin bands in 
74.2% of the patients that were tested, a figure 
lower that in non-compromised patients (85.7%). 
Similar findings had been previously presented by 
Tobón et al. in a smaller series (32). Despite this 
promising result, a more extensive study aimed at 
evaluating the effectiveness on serologic tests in 
patients with various types of immunosuppression 
should be carried out. Antigen detection should be 
included in the new studies as they are reliable, 
faster and adequate diagnostic procedures in 
immunosupressed patients (7,42).
Exception made of fluconazole prescription for 
11.4% of the cases, something that is against 
present recommendations patients were treated 
according to the current guidelines (43). However 
no further assessment of treatment results could 
be made due to the temporal nature of the survey.
This survey has important limitations because the 
quality of the data suffers while the larger volume 
of information brings forth important determinants. 
The fact that the questionnaires were answered 
voluntarily may impact on case distribution in function 
of the availability of diagnostic resources and of 
the interest and knowledge of the local physicians. 
Nonetheless, few studies have included a similar 
number of histoplasmosis cases, numbers that have 
allowed the establishment of valid comparisons on 
risk factors thus furnishing significant information 
concerning this fungal disorder in Colombia.
In conclusion, histoplasmosis is a frequent 
disease in Colombia, especially in certain risk 
factor groups and whose clinical manifestations 
and epidemiologic behavior vary according to the 
patient´s immunosuppression. Additional efforts 
should be done in order to identify and diagnose 
the mycosis in individuals with compatible 
manifestations and risk factors in order to establish 
an early diagnosis and treatment thus limiting the 
seriousness of the disease course and reducing its 
mortality and morbidity.
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CIB-INS
ENCUESTA EPIDEMIOLÓGICA HISTOPLASMOSIS
Datos del paciente
Nombre y apellido
Año de nacimiento Sexo M F Nº documento de identidad
Departamento de nacimiento Departamento de residencia Teléfono
Factores de riesgo (marque con una X el dato) Sí No Sin dato
Infección por VIH
Número de células CD4+/ml
Uso de corticosteroides
Enfermedad autoinmuni taria
¿Cuál?
Trasplante
Órgano trasplantado
Tumor sólido
Tipo de tumor
Neoplasia maligna hematológica
Tipo de neoplasia
Diabetes mellitus
Factores de riesgo ocupacional (marque con una X el dato)
Exposición a excretas de aves
Murciélagos
Remoción de tierra
Trabajo de demolición
Visita a cuevas
Antecedentes de viajes
¿Cuánto hace?
Otro factor
¿Cuál?
Sin factor de riesgo aparente
¿Fue la histoplasmosis la enfermedad indicadora de sida?
Diagnóstico de histoplasmosis
Fecha Día Mes Año Caso nuevo Recaída
Fecha inicial de los síntomas
Prueba diagnóstica (marque con una X el dato) Positiva Negativa No practicada
Detección de anticuerpos
FC-tí tulo
ID-bandas H M NR
Antigenuria
Resultado
PCR
Resultado
Cultivo para Histoplasma spp.
¿De qué muestra? LCR
Sangre
Lavado broncoalveolar
Orina
Esputo
Otro (especificar)
Estudio histopatológico
¿Cuál órgano o tejido?
Hemoglobina
¿Resultado? Anemia leve: Hb=9
Anemia moderada: Hb 7-9
Anemia grave: =7
Leucopenia
Trombocitopenia
Día Mes Año
Supplement 1. Colombian histoplasmosis questionnaire
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Imágenes diagnósticas (1) (marque con una X el dato) Sí No Nopracticada
Radiografía de tórax
Normal
Anormal
¿Resultado? Infilt rados alveolares
Infiltrados intersticiales
Infiltrados mixtos
Cavidades
Calcificaciones
Compromiso pleural
Otra (especificar)
Manifestaciones clínicas (marque con una X el dato) Sí No Sin dato
Fiebre (temperatura =38 ºC)
Pérdida de peso
Anorexia y adinamia
Tos
Expectoración
Disnea
Dolor pleurítico
Hipertrofia linfática
¿Localización? Cervical
Axilar
Intraabdominal
Epitroclear
Inguinal
Hepatomegalia
Esplenomegalia
Lesiones en piel
Localizadas (especif icar)
Diseminadas
Eritema nudoso
Lesiones en mucosas
¿Dónde? Oral
Nasal
Tubo digestivo
Signos meníngeos
¿Cuál? Cefalea
Vómito
Alteraciones del estado de la conciencia
Otras (especificar)
Clasificación de la histoplasmosis (marque con una X la que corresponda)
B390 Infección pulmonar aguda debida a H. capsulatum B391 Infección pulmonar crónica debida aH. capsulatum
B392 Infección pulmonar debida aH. capsulatum, sin otra
especif icación
B393 Infección diseminada debida a H. capsulatum
B394 Histoplasmosis debida aH. capsulatum, sin otra especificación B399 Histoplasmosis, no especificada
Tratamiento para la histoplasmosis
Medicamento Dosis/día Tiempo
Inicial
Mantenimiento
Profilaxis secundaria
Resultado del tratamiento
Mejoría Recaída Muerte Tiempo de recaída o muerte
Otros tratamientos
Antituberculo
so
Antirretroviral Esteriodes Otro (¿Cuál?)
Condición al egreso (marque con una X el dato)
Vivo Muerto Sin dato
Profesional(es) responsable(s): clínico/bacteriólogo
Nombre Dirección
Teléfono FAX Dirección electrónica
Firma Fecha
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Supplement 2. Incidence of histoplasmosis in Colombian patients by department, 2005-2008 
Department Number Mean Population Incidence cases  
 cases    to 2005  x 100,000 
Antioquia 105 26.25 5,682,276 0.462 
Valle 21 5.25 4,161,425 0.126 
Cundinamarca (Bogotá) 17 4.25 9,120,153 0.047 
Norte de Santander  2 0.50 1,243,975 0.040 
Caldas  1 0.25 968,740 0.026 
Meta  5 1.25 783,168 0.160 
Risaralda 1 0.25 897,509 0.028 
Bolívar 2 0.50 1,878,993 0.027 
Casanare  1 0.25 295,353 0.085 
Boyacá 1 0.25 1,255,311 0.020 
ND 2    
Total 158   
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Demographic data
Males, •	 n=332
Patients <15 years of age, •	 n=17
Adult patients, n=417
Total patients, n=434
Clinical manifestations recorded, n=394 adults/417
                           17 children/17
Lung X-rays lesions recorded, n=293/384 total examined
Therapy prescribed to adults, n = 299/417 total treated
Therapy prescribed to children, n=10/17 total treated
Total questionnaries received
from histoplasmosis patients
enrolled in study
(n=434)
           Diagnosis established by (adult patients)
Isolation of H. capsulatum, n=242 of  253 cultured•	
Precipitin bands in the ID test, n=144 of 194 processed•	
Reactive in the CF test, n=92 of 190 processed•	
Wright or histological stains with yeasts, n=207 of 357 examined•	
Supplement 3. Number of patients included in the study according to demographic, clinical and diagnostic test data
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Supplement 4. Demographic characteristics of the 417 adult patients with histoplasmosis according to the risk factor reported 
(1992-2008)
Characteristic Risk factor  
 AIDS OI1 Occupational NR2 Total
 (n=294) (n=29) (n=51)  (n=43) (n=417)
Age (years)
(SD+)3 35.1 51.2 40.3 48.9 38.4
 (±9.2) (±15.6) (±14.2) (±13.9) (±12.3) 
Sex 
Male4, n (%) 251 (85.4) 16 (55.2) 33 (64.7) 21 (48.8) 321(77.0)
1  Other immunodeficiency: steroids (n=13), cancer (n=7), transplant (n=4), diabetes (n=2), cirrhosis (n=1), alcoholism (n=1), 
malnutrition (n=1)
2  No risk factor informed
3  OR=16.65, CI95% 10.88-22.43, p<0.01 between AIDS and other immunodeficiency
4  OR=5.14, CI95% 2.31–11.42, p<0.01 between AIDS and other immunodeficiency
